Menu Back toSession-7-Update-on-New-Treatments

Pharmacovigilance and Risk Management Strategies Conference

Session 7: Update on New Treatments

    Session Chair(s)
      Stella  Blackburn

      Stella Blackburn

      • Vice President, Global Head of Early Access and Risk Management
      • IQVIA, United Kingdom
    Pharmacovigilance is similar to a detective story. We are trying to determine whether the adverse event is due to a drug, the diseases the patient is being treated for or something intrinsic to the patient. To do this we need an understanding of both the drug mechanisms of action and the context in which drug is used. New classes of treatments are being developed all the time with increasingly complex and specific mechanisms. This session will provide an overview of three emerging therapies from a clinical point of view: CAR-T cells, monoclonal antibodies – targeted therapies and checkpoint inhibitors – and gene therapy.
      David Takura Chonzi

      Chimeric Antigen Receptor (CAR) T Cell Therapy

      David Takura Chonzi

      • Vice President of Patient Safety and Risk Management
      • Kite, A Gilead Company, United States
      Jacques   P. Tremblay, PhD

      The New CRISPR/Cas9 Technology

      Jacques P. Tremblay, PhD

      • Deputy Editor, Molecular Therapy and Cell Transplantation;Professor, Department
      • Laval University, Canada
      Jeffrey  Anderson, MD, PhD


      Jeffrey Anderson, MD, PhD

      • HCC Program Lead Oncology Clinical Development
      • Bristol-Myers Squibb, United States